Alteogen is expanding its business scope by absorbing its subsidiary Alteogen Biologics through a merger. The strategy is to establish a foundation enabling the company to independently conduct not only new drug candidate development but also clinical trials, approvals, and pharmaceutical manufacturing and sales.

According to Alteogen's announcement on the 11th, the company's board of directors approved the absorption merger of Alteogen Biologics at a meeting on the 6th, with the merger scheduled for December 29. Alteogen currently holds a 62.9% stake in the subsidiary.

■ From Development to Commercialization... Changes in the Business Portfolio

The core of this merger lies in transforming Alteogen's business portfolio. The approach combines the competitiveness of the bio technology platform it has accumulated with the subsidiary's drug development experience and sales organization.

Alteogen Biologics has built a development track record in the field of ophthalmic disease treatments. Its flagship product is ALT-L9, a biosimilar of Eylea, which has completed global Phase 3 clinical trials and received approval in Europe. The company has also participated in developing ALTS-OP01, a candidate for treating macular degeneration, and has handled sales and marketing for pharmaceuticals including Tergazeju.

Once these business assets are merged into the parent company, Alteogen will expand its organizational foundation to pursue its own drug development beyond its existing platform technologies. In particular, securing new drug candidates for ophthalmic diseases is expected to bring changes to its future research and development strategy. However, the candidates under development must undergo additional research, clinical trials, and approval procedures before reaching actual commercialization.

■ 600,047 New Shares to Be Issued... Merger Ratio of 1 to 0.1679581

The scale of share issuance for the merger has also been disclosed. Alteogen plans to issue a total of 600,047 new shares to the subsidiary's shareholders, with a merger ratio of 1 to 0.1679581 for Alteogen and Alteogen Biologics, respectively. New shares will not be issued for the subsidiary stake Alteogen already owns.

The company stated that the process of determining the merger terms involved valuation by external experts as well as legal and financial reviews. A special committee composed of independent directors also reviewed the necessity of the transaction, its impact on shareholders, and the appropriateness of the valuation criteria before recommending the merger.

This organizational restructuring is also linked to plans for production facility investment. Alteogen plans to pursue both expanding its production base and integrating the subsidiary, building a structure that can manage the commercialization process following research and development. By utilizing the sales and marketing organization previously operated by the subsidiary, the company can also reduce the burden of building a new sales organization if its independently developed products receive approval and enter the market.

■ ALT-B4 Hybrozyme Platform + Own Pipeline, Key to Results

Attention is also focused on what business results the Hybrozyme platform, Alteogen's main business, and the newly secured proprietary development pipeline will deliver. If drug development and sales functions are added to businesses utilizing the technology platform, revenue generation methods could diversify. However, the merger itself does not guarantee improved performance, and actual results are expected to depend on product development progress, approval outcomes, and sales performance.

A schedule for briefings for shareholders has also been arranged. Alteogen Biologics will hold a shareholder meeting on October 14 and Alteogen on the 15th, with Alteogen's meeting to take place in Daejeon. The company plans to post merger-related materials on its website and accept shareholders' questions and opinions, reflecting them in follow-up explanatory materials.

Ultimately, the key issue of this merger is tangible business performance after the organizational integration. Whether Alteogen can extend the competitiveness it has built on its existing technology platform into independent drug development and commercialization will be a point to watch in the mid to long term.

[Investment decisions and responsibilities rest with the investor. AI assistance was used in composing the sentences of this article.]